R

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Rabbit anti-human thymocyte immunoglobulin (Thymoglobuline®) (489/08)	Immunosuppression in solid organ transplantation	Not recommended	82	Aug/Sept 2008
Rabeprazole (Pariet®)	Symptomatic GORD without oesophagitis – on-demand therapy		47 44	2004
Rabeprazole (Pariet®)	Zollinger-Ellison syndrome	Not recommended	55	2006
Racecadotril (Hidrasec Infants®, Hidrasec Children®) (818/12)	Acute diarrhoea in infants	Not recommended	140 123	Jul/Aug 2014 Jan 2013
Racecadotril (Hidrasec®) (832/12)	Acute diarrhoea in adults	Not recommended	123	Jan 2013
Radium-223 dichloride (Xofigo®) (1077/15)	For the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.	Non-formulary - absence of Clinician demand	152	Nov/Dec 2015
Raltegravir 100mg granules for oral suspension (Isentress®) SMC2101	In combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.	Not available as not recommended for use in NHS Scotland	170	Sep 2018
Raltegravir 600mg film-coated tablets (Isentress®) SMC No 1280/17	In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and paediatric patients weighing at least 40kg.	Available in line with National Guidance	165	Jan 2018
Raltegravir (Isentress®) for adults and children (1102/15)	For treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants	Formulary - Hospital Use (HIV and Paediatrics)	152	Nov/Dec 2015

	from the age of 4 weeks			
Raltegravir (Isentress®) for children (1113/15)	For reatment of human immunodeficiency virus (HIV-1) infection in children from the age of 4 weeks to <2 years	Formulary - Hospital use (HIV Paediatrics)	152	Nov/Dec 2015
Raltegravir (Isentress®) (902/13)	Patients who are intolerant or resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs)	HOSPITAL ONLY Paediatrics under supervision of HIV specialists in Glasgow and Edinburgh	130	Sept/Oct 2013
Raltegravir (Isentress®) (613/10)	HIV-1 infection	HOSPITAL ONLY (HIV Clinic)	96 79	Apr/May 2010 May 2008
Ramucirumab 10 mg/ml concentrate for solution for infusion (Cyramza®) SMC2291	In combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.		185	July 2021
Ramucirumab 10mg/mL concentrate for solution for infusion (Cyramza®) SMC2246	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib		178	Feb 2020
Ramucirumab (Cyrmaza®)1176/16	In combination with paclitaxel for the treatment of adults patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. As monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyramidine chemo-therapy, for whom treatment in combination with paclitaxel is not appropriate.	Not available as not recommended for use in NHS Scotland	156	Sep 2016
Ramicurinab 10mg concentrate for solution for infusion (Cyrmaza®) SMC 1156/16	In combination with FOLFIRI (irinocetan, folinic acid and 5-fluorouaracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaloplatin and a fluoropyramidine	Not available as not recommended for use in NHS Scotland	155	June 2016

Ranibizumab 10mg/mL solution for injection / 10mg/mL solution for injection in pre-filled syringe (Lucentis®) SMC 2270	Is not recommended for use within NHSScotland. Treatment of proliferative diabetic retinopathy in adults.	For information only	180	Sept 2020
Ranibizumab (Lucentis®) (907/13)	Treatment for visual impairment due to choroidal neovascularisation secondary to pathlogic myopia in adults.	HOSPITAL ONLY (Ophthalmology)	132	Nov/Dec 2013
Ranibizumab (Lucentis®) (711/11)	Treatment of visual impairment due to diabetic macular oedema (DMO) in adults.	HOSPITAL ONLY (Ophthalmology)	124 123	Feb 2013 Jan 2013
Ranibizumab (Lucentis®) (732/11)	For the treatment of visual impairment due to macular oedema (MO) secondary to retinal vein occlusion (RVO) (branch RVO or central RVO) in adults.	HOSPITAL ONLY	127 112 109	May 2013 Dec 2011 Sept 2011
Ranibizumab (Lucentis®) (381/07)	Treatment of neovascular (wet) age-related macular degeneration (AMD)	HOSPITAL ONLY (Ophthalmology Clinic)	69	June 2007
Ranolazine (Ranexa®) (565/09)	Stable angina Pectopris	Not recommended	122 114 101 92	Dec 2012 Feb 2012 Dec 10/Jan 2011 Aug/Sept 2009
Rasagiline (Azilect®)	Idiopathic Parkinson's disease as monotherapy	Not recommended	64 56	2006
Rasagiline (Azilect®)	Idiopathic Parkinson's disease as adjunct therapy Parkinson's disease	Not recommended	64 56	2006
Ravulizumab (Ultomiris) SMC2330	For the treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab. SMC restriction: under the advice of the national renal	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	185	July 2021

	complement therapeutics service Two single-arm, phase III studies demonstrated the beneficial treatment effect of ravulizumab on complete thrombotic microangiopathy (TMA) response, defined as normalisation of haematological parameters and improvement in renal function.			
Ravulizumab 300mg concentrate for solution for infusion (Ultomiris®) SMC2305	For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): • In patients with haemolysis with clinical symptom(s) indicative of high disease activity • In patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. SMC restriction: under the advice of the national PNH service	Available in line with local guidance for prescribing	183	March 2021
Ravulizumab concentrate for solution for infusion (Ultomiris®) SMC2658	Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody positive.	Not available as not recommended for use in NHS Scotland	197	May/June 2024
Ravulizumab concentrate for solution for infusion (Ultomiris®) SMC2657	As an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.	Not available as not recommended for use in NHS Scotland	197	May/June 2024
Recombinant E.coli asparaginase 10,000 units powder for concentrate for solution for infusion (Spectrila®) SMC No 1319/18	As a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults. Asparaginase produced in E. coli cells has been used in NHS Scotland as an unlicensed medicine as part of treatment of ALL in children and adults; asparaginase (Spectrila®) provides a licensed alternative.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	168	May 2018
regorafenib film-coated tablets (Stivarga) SMC2562	as monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.	Available in line with national guidance	195	December 2023

Regorafenib 40mg film-coated tablets (Stivarga®) SMC No 1316/18	As monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib.	Available in line with national guidance	169	July 2018
Regorafenib (Stivarga®) (1118/15)	Adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies.	Not recommended	152	Nov/Dec 2015
Regorafenib (Stivarga®) (1031/15)	Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib	Non-Formulary - Absence of clinician demand Supplied via a patient access scheme	147	Apr 2015
Relugolix, estradiol, norethisterone acetate film-coated tablets (Ryeqo®) SMC2666	In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. Relugolix, estradiol, norethisterone acetate film-coated tablets (Ryeqo®), compared with placebo, resulted in statistically and clinically significant improvements in treatment response (menstrual and non-menstrual pelvic pain) after 24 weeks in women with moderate-to-severe pain associated with endometriosis.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Relugolix film-coated tablets (Orgovyx®) SMC2678	• For the treatment of adult patients with advanced hormone-sensitive prostate cancer • For the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy • As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Relugolix 40mg, estradiol 1mg, norethisterone acetate 0.5mg film-coated tablets (Ryeqo®) SMC2442	Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. SMC restriction: for use in patients who have failed or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for	190	August 2022

	delivery systems. Relugolix, estradiol, norethisterone acetate tablets (Ryeqo®), compared with placebo, significantly reduced menstrual blood loss volume in patients with uterine fibroids and heavy menstrual bleeding.	alternative medicines.		
Remdesivir (Veklury®) SMC2550	following SMC collaboration with NICE on TA971: remdesivir and tixagevimab plus cilgavimab for treating COVID-19.	Available in line with local guidance	197	May 2024
Remimazolam powder for concentrate for solution for injection/infusion (Byfavo®) SMC2692	In adults for intravenous induction and maintenance of general anaesthesia.	Not recommended for use in NHS Scotland	198 not yet published	
Remimazolam 20mg powder for solution for injection (Byfavo®) SMC2454	In adults for procedural sedation. In three randomised, multicentre, phase III studies, remimazolam treatment resulted in a significantly higher rate of procedure success in patients undergoing colonoscopy or bronchoscopy when compared with placebo.	Not available as not recommended for use in NHS Scotland	190	August 2022
Retapamulin (Altargo®) (472/08)	Impetigo and infected small wounds	Not recommended	78	Apr 2008
Retigabine (Trobalt®) (712/11)	Adjunctive treatment of partial onset seizures	GPs may prescribe under the direction of the Neurology Clinic	111 109	Nov 2011 Sept 2011
Reslizumab 10mg/mL concentrate for solution for infusion (Cinqaero®) SMC No 1233/17	As add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.	Not available as not recommended for use in NHS Scotland	166	Feb 2018
Rezafungin acetate powder for concentrate for solution for infusion (Rezzayo®) SMC2659	For the treatment of invasive candidiasis in adults. SMC restriction: use should be on the advice of local microbiologists or specialists in infectious disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		

Ribociclib 200mg film-coated tablets (Kisqali®) SMC2198	For the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy, or in women who have received prior endocrine therapy. SMC restriction: women who have relapsed on or within 12 months of completing (neo) adjuvant endocrine therapy, or those who have progressed on first-line endocrine-based therapy for advanced breast cancer.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	178	Feb 2020
Ribociclib 200mg film-coated tablets (Kisqali®) SMC No 1295/18	In combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.	Available in line with national guidance	168	May 2018
Ritlecitnib hard capsules (Litfulo) SMC 2610	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In a randomised, double-blind, phase IIb/III study in patients with severe alopecia areata, ritlecitinib was associated with statistically significant improvements in scalp hair regrowth versus placebo at week 24	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	197	May 2024
Rifampicin (Voractiv®) (876/13)	Initial treatment of tuberculosis	Not recommended	127	May 2013
Rifaximin (Targaxan®) (893/13)	Reduction in recurrence of episodes of overt hepatic encephalopathy (HE) > 18 years of age	GPs under the direction of Gastroenterology	130	Sept/Oct 2013
Rifaximin (Xifaxanta®) (806/12)	Travellers' diarrhoea	Not recommended	119	Aug/Sept 2012
Rilpivirine/emtriciabine/tenofovir alafenamide 200mg/25mg/25mg film-coated tablets (Odefsey®) SMC 1189/16	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse	Available in line with national guidance	158	Dec 2016

	transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.			
Rilpivirine 25mg film-coated tablet (Edurant®)	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV1) infection in antiretroviral treatment naïve patients aged12 to 18 years of age and older with a viral load (VL)≤ 100,000 HIV-1RNA copies/ml	Available from a specialist Centre in another Board	156	Sep 2016
Rilpivirine (Edurant®) (758/12)	HIV-1	HOSPITAL ONLY (HIV Clinic)	115	Mar/Apr 2012
Rimegepant oral lyophilisate (Vydura®) SMC2603	For the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. SMC restriction: for patients with episodic migraine who have at least 4 migraine attacks per month, but fewer than 15 headache days per month and who have had prior failure on three or more migraine preventive treatments	Not routinely available as local implementation plans are being developed	195	December 2023
Rimegepant oral lyophilisate (Vydura®) SMC2521	For the acute treatment of migraine with or without aura in adults. SMC restriction: for patients who have had inadequate symptom relief after trials of at least two triptans or in whom triptans are contraindicated or not tolerated; and have inadequate pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	193	June 2023
Rimegepant oral lyophilisate (Vydura®) SMC2567	For the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.	Not available as not recommended for use in NHS Scotland	193	June 2023
Rimonabant (Acomplia®)	Obesity in patients with risk factors	Not recommended	66	Feb 2007
Riociguat (Adempas®) (1056/15)	Pulmonary arterial hypertension (PAH): as monotherapy or in combination with endothelin receptor antagonists, for the treatment of adult patients with PAH with World Health Organisation Functional Class (WHO FC) II to III to improve exercise capacity.	HOSPITAL ONLY (Under the direction of the Scottish Pulmonary Vascular Centres)	150	June 2015

Riociguat (Adempas®) (1001/14)	CTEPH	Non-formulary - restricted to the Scottish Pulmonary Vascular Unit (tertiary referral)	144	Jan/Feb 2015
ripretinib tablets (Qinlock®) SMC2722	for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Not available as not recommended for use in NHS Scotland		
Risankizumab solution for injection in cartridge and concentrate for solution for infusion (Skyrizi®) SMC2686	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. Risankizumab offers an additional treatment choice in the therapeutic class of interleukin inhibitors.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Risankizumab 600mg concentrate for solution for infusion and 360mg solution for injection (Skyrizi®) SMC2534	For the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.	PAEDS Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	Dec 2023
Risankizumab 150mg solution for injection in a prefilled syringe or pen (Skyrizi®) SMC2459	Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). SMC restriction: (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy (biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional DMARDs and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		

Risankizumab 75mg solution for injection in pre-filled syringe (Skyrizi®) SMC2196	For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Available in line with local guidance for prescribing	177	Dec 2019
risdiplam 0.75mg/mL powder for oral solution (Evrysdi®) SMC2401	for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies. Evidence from two phase II/III studies has indicated that risdiplam improves motor milestones and motor function in patients with type 1, 2 and 3 SMA.	ADULT SERVICES - Available in line with local guidance PAEDIATRICS - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2022
Risedronate (Actonel®) (424/07)	Osteoporosis in men	Not recommended	75	Dec 2007
Risedronate (Actonel® once a week)	Osteoporosis in postmenopausal women		26	2003
Risperidone depot (Risperdal Consta®)	Schizophrenia	HOSPITAL ONLY (Mental Health specialist list)	23 Protocol	2002
Risperidone (Risperdal®)	Mania in bipolar disorder		43	2004
Risperidone (Risperdal Quicklet®) (403/07)	Schizophrenia, bipolar disorder		72	Sept 2007
Ritonavir and nirmatrelvir (Paxlovid®) SMC2557	Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.			March 2024
Rituximab 100mg Concentrate for Solution for Infusion (MabThera®) SMC2193	Treatment of patients with moderate to severe pemphigus vulgaris.	Not available as not recommended for use in NHS Scotland	175	Aug 2019
Rituxumab 100mg, 500mg solution for infusion (MabThera®) SMC2165	In combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).	Not available as not recommended for use in NHS Scotland	174	May 2019

Rituximab (MabThera®) (975/14)	Non-Hodgkin's lymphoma (NHL) in adults	HOSPITAL ONLY (Haematology)	140	Jul/Aug 2014
Rituximab (MabThera®) (894/13)	Adults with severe, active granulomatosis with polyangitis (Wegener's) (GPA) and MPA	HOSPITAL ONLY	131 130	Oct/Nov 2013 Sept/Oct 2013
Rituximab (MabThera®) (591/09)	Chronic lymphocytic leukaemia (CLL)	HOSPITAL ONLY (Haematology)	108 Protocol 94 90	Aug 2011 Dec 09/Jan 10 June 2009
Rituximab (MabThera®)	CD20 +ve large B-cell NHL		25	2003
Rituximab (MabThera®) (493/08)	First-line treatment of stage III-IV follicular lymphoma	HOSPITAL ONLY	82 47	Aug/Sept 2008 2004
Rituximab (MabThera®)	Severe active rheumatoid arthritis (RA)	HOSPITAL ONLY (Rheumatology Clinic)	72 Protocol 63	Sept 2007 2006
Rituximab (MabThera®) (675/11)	Maintenance therapy for follicular lymphoma responding to induction	HOSPITAL ONLY (Haematology)	118 103	July 2012 Feb/Mar 2011
Rituximab (MabThera®)	Maintenance therapy for relapsed/refractory follicular lymphoma		64	2006
Rivaroxaban 2.5mg film-coated tablet (Xarelto®) SMC2128	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery disease at high risk of ischaemic events. SMC restriction: use in patients with stable coronary artery disease that does not require dual antiplatelet therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	174	May 2019
Rivaroxaban (Xarelto®) (1062/15)	Rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute	Not recommended	150	June 2015

	coronary syndrome (ACS) with elevated cardiac biomarkers.			
Rivaroxaban (Xarelto®) (775/12)	DVT	Formulary - first line Note: A dose reduction is no longer required if eGFR is 30-49mls/min for treatment of PE/DVT only. See Supplement No 127 May 2013	115	Mar/Apr 2012
Rivaroxaban (Xarelto®) (852/13)	Pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults	Formulary - first line	128 (update) 126	June/July 2013 Apr 2013
Rivaroxaban (Xarelto®) (756/12)	Prevention of stroke and systemic embolism in adults	Formulary - first line new oral anticoagulant Note: A dose reduction is no longer required if eGFR is 30-49mls/min for treatment of PE/DVT only. See Supplement No 127 May 2013	115	Mar/Apr 2012
Rivaroxaban (Xarelto®) (519/08)	VTE in adults	HOSPITAL ONLY (Orthopaedics)	86 Protocol 85	Dec 2008
Rivastigmine transdermal patch (Exelon®)	Moderately severe Alzheimer's dementia		97 75	June/July 2010 Dec 2007
Rivastigmine (Exelon®)	Mild to moderately severe dementia in patients with Parkinson's disease.	Not recommended	60	2006
Roflumilast, 500 microgram, film-coated tablet (Daxas®) SMC No. (635/10)	For maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1]) post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.	Not available as not recommended for use in NHS Scotland	100 164	Oct 2017

Rolapitant (as hydrochloride monohydrate) 90mg film-coated tablets (Varuby®) SMC No. (1266/17)	Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy	Available in line with national guidance	164	Oct 2017
Romiplostim 125 micrograms, 250 micrograms,500 micrograms powder for solution for injection (Nplate®) SMC2126	Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). SMC restriction: to use in patients with severe symptomatic ITP or patients with a high risk of bleeding.	Available from a specialist centre in another NHS Board	174	May 2019
Romiplostim (Nplate®) (553/09)	Idiopathic Thrombocytopenic purpura (ITP)	HOSPITAL ONLY Non-formulary (Haematology)	93	Oct/Nov 2009
Romosozumab 105mg solution for injection in pre-filled pen (Evenity®) SMC2280	Treatment of severe osteoporosis in postmenopausal women at high risk of fracture. SMC restriction: to use in patients who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months).	Available in line with local guidance for prescribing	182	January 2021
Ropeginterferon alfa-2b solution for injection in pre-filled pen (Besremi®) SMC2563	As monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	Not available as not recommended for use in NHS Scotland	194	September 2023
Ropeginterferon alfa-2b 250 micrograms/0.5 ml solution for injection in pre-filled pen (Besremi®) SMC2421 AOP Orphan Ltd	As monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. In a phase III study, ropeginterferon alfa-2b failed to demonstrate non-inferiority to hydroxycarbamide in treatment-naïve patients who required cytoreductive therapy and in patients who had a partial response to hydroxycarbamide.		189	May 2022
Ropinirole (Requip® XL®) (491/08)	Idiopathic Parkinson's disease	Non-formulary	82	Aug/Sept 2008
Ropinirole (Adartrel®)	Moderate to severe idiopathic restless legs syndrome (RLS)	Formulary	60 151	2006 2015
Rosiglitazone (Avandia®)	Triple therapy in type 2 diabetes	Discontinued	98	Aug/Sept

Discontinued November 2010			52	2010 2005
Rosiglitazone (Avandia®) Discontinued November 2010	Type 2 diabetes mellitus (monotherapy)	Discontinued	98 75 67 43 37	Aug/Sept 2010 Dec 2007 Mar 2007 2004
Rosiglitazone/metformin (Avandamet®) Discontinued November 2010	Triple therapy in type 2 diabetes	Discontinued	98 67 60	Aug/Sept 2010 Mar 2007 2006
Rosiglitazone/metformin (Avandamet®) Discontinued November 2010	Type 2 diabetes mellitus	Discontinued	98 61 49 47 39 37	Aug/Sept 2010 2006 2004
Rosuvastatin (Crestor®) (725/11)	Lipid lowering	Not recommended	111 89 26	Nov 2011 2009 2003
Rotigotine 1mg, 2mg and 3mg per 24 hours transdermal patch (Neupro®) (548/09)	Symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults	Formulary	94 92 151	Dec 09/Jan 10 Aug/Sep 09 Sep/Oct 15
Rotigotine transdermal patch (Neupro®)	Advanced Parkinson's disease in combination with levodopa		81 72	July 2008 Sept 2007
Rotigotine transdermal patch (Neupro®)	Early-stage idiopathic Parkinson's disease		81 71 60	July 2008 July 2007 2006
Ropeginterferon alfa-2b solution	As monotherapy in adults for the treatment of polycythaemia	Not available as not	194	September

for injection in pre-filled pen (Besremi®) SMC2563	vera without symptomatic splenomegaly.	recommended for use in NHS Scotland		2023
Roxadustat 20mg, 50mg, 70mg, 100mg and 150mg film-coated tablets (Evrenzo®) SMC2461	Treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD). SMC restriction: for use in patients who are non-dialysis dependent (NDD) at the time of treatment initiation. Roxadustat was non-inferior to an erythropoiesis stimulating agent (ESA) and superior to placebo for improving haemoglobin (Hb) levels in adults with anaemia in CKD who were NDD.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	190	August 2022
Rozanolixizumab solution for injection (Rystiggo®) SMC2761	As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gmg) in adult patients who are anti-acetylcholine receptor (achr) or anti-muscle-specific tyrosine kinase (musk) antibody positive.	Not available as not recommended for use in NHS Scotland		
Rucaparib 200mg, 250mg, 300mg film-coated tablets (Rubraca®) SMC 2224	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. SMC restriction: to patients who do not have a BRCA mutation	Available in line with national guidance	180	Sept 2020
Rucaparib 200mg, 250mg and 300mg film-coated tablets (Rubraca®) SMC2221	As monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.	Not available as not recommended for use in NHS Scotland	176	Oct 2019
Rufinamide 40mg/mL oral suspension and 100mg, 200mg, 400mg tablets (Inovelon®) SMC2146	As adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to ≤4 years. SMC restriction: restricted to use in patients who have failed treatment with or are intolerant of other antiepileptic drugs	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	174	May 2019
Rufinamide (Inovelon®) (795/12)	Adjunctive therapy in the treatment of seizures associated with	GPs under the direction of the	119	Aug 2012

	Lennox-Gastaut syndrome	Paediatric Neurology Clinic	152	Nov/Dec 2015
Rufinamide (Inovelon®) (416/07)	Seizures associated with Lennox-Gastaut syndrome	GPs under the direction of the Paediatric Neurology Clinic	84 74 152	Nov 2008 Nov 2007 Nov/Dec 2015
Rupatadine (Rupafin®) (612/10)	Allergic rhinitis and chronic idiopathic urticaria	Not recommended	95	Feb/Mar 2010
Ruxolitinib tablets (Jakavi®) SMC2750	For the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids. In a randomised, open-label, phase III study, ruxolitinib treatment resulted in a statistically significant improvement in overall response rate compared with best available therapy in patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.			
Ruxolitinib cream (Opzelura®) SMC2634	For the treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.	Not recommended for use in NHS Scotland	197	May 2024
Ruxolitinib 5mg, 10mg, 15mg and 20mg tablets (Jakavi®) SMC2498	For the treatment of: • patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids • patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids	Not available as not recommended for use in NHS Scotland	190	Aug 2022
Ruxolitinib phosphate 5mg, 10mg, 15mg, 20mg tablets (Jakavi®) SMC2213	The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide).	Available in line with local guidance for prescribing	178	Feb 2020
Ruxolitinib (Jakavi®) (867/13)	Disease-related splenomegaly	Not recommended	127	May 2013
Ruxolitinib (as phosphate) (Jakavi®) (867/13)	The treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis	HOSPITAL ONLY - (Haematology) Supplied via a Patient Access	146	Mar 2015

	or post essential thrombocythaemia myelofibrosis.	Scheme		

Updated: 9th May 2025

Back to top Back to homepage